GS
ALXN

GAM Systematic’s Alexion Pharmaceuticals ALXN Stock Holding History

GAM Systematic’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$193K Buy
+1,378
New +$187K 0.03% 513

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GAM Systematic's ALXN Position: Q3 2017 in Review

GAM Systematic opened a new position in Alexion Pharmaceuticals (ALXN) in Q3 2017: 1,378 shares worth $193K. The stake represents 0.03% of the portfolio and ranks #513 among its holdings.

595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • GAM Systematic held 1,378 shares of Alexion Pharmaceuticals worth $193K as of Q3 2017.
  • Alexion Pharmaceuticals was a new GAM Systematic position in Q3 2017.
  • Alexion Pharmaceuticals made up 0.03% of GAM Systematic's portfolio in Q3 2017, its #513 holding.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on GAM Systematic's 13F filing for Q3 2017, filed 14 Nov 2017.